Docality.com Logo
 
Dr. Brooks  Betts  Do image

Dr. Brooks Betts Do

280 Farner Place
The Villages FL 32163
352 741-1710
Medical School: Philadelphia College Of Osteopathic Medicine - 1980
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: Yes
Participates In EHR: Yes
License #:
NPI: 1982653325
Taxonomy Codes:
207Q00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Brooks Betts is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$315.00 Average Price Allowed
By Medicare:
$155.52
HCPCS Code:99305 Description:Nursing facility care init Average Price:$250.00 Average Price Allowed
By Medicare:
$124.30
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$205.03 Average Price Allowed
By Medicare:
$100.25
HCPCS Code:99309 Description:Nursing fac care subseq Average Price:$170.00 Average Price Allowed
By Medicare:
$84.41
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$140.00 Average Price Allowed
By Medicare:
$67.70
HCPCS Code:99308 Description:Nursing fac care subseq Average Price:$130.00 Average Price Allowed
By Medicare:
$64.22
HCPCS Code:90732 Description:Pneumococcal vaccine Average Price:$115.00 Average Price Allowed
By Medicare:
$63.98
HCPCS Code:G0009 Description:Admin pneumococcal vaccine Average Price:$45.00 Average Price Allowed
By Medicare:
$22.64
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$45.00 Average Price Allowed
By Medicare:
$22.64
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$40.00 Average Price Allowed
By Medicare:
$18.05
HCPCS Code:Q2038 Description:Fluzone vacc, 3 yrs & >, im Average Price:$30.00 Average Price Allowed
By Medicare:
$12.18
HCPCS Code:J1030 Description:Methylprednisolone 40 MG inj Average Price:$10.00 Average Price Allowed
By Medicare:
$3.43

HCPCS Code Definitions

J1030
Injection, methylprednisolone acetate, 40 mg
G0009
Administration of pneumococcal vaccine
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99309
Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient has developed a significant complication or a significant new problem. Typically, 25 minutes are spent at the bedside and on the patient's facility floor or unit.
G0008
Administration of influenza virus vaccine
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99308
Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 15 minutes are spent at the bedside and on the patient's facility floor or unit.
99305
Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 35 minutes are spent at the bedside and on the patient's facility floor or unit.
Q2038
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1437117116
Dermatology
1,316
1669405312
Pulmonary Disease
736
1710952486
Cardiovascular Disease (Cardiology)
692
1295796902
Cardiovascular Disease (Cardiology)
512
1992725089
Internal Medicine
307
1730155672
Urology
300
1639132269
Medical Oncology
283
1972543312
Ophthalmology
259
1518933183
Gastroenterology
258
1821065657
Family Practice
255
*These referrals represent the top 10 that Dr. Betts has made to other doctors

Publications

Combined Measurement of the Higgs Boson Mass in pp Collisions at sqrt[s]=7 and 8 TeV with the ATLAS and CMS Experiments. - Physical review letters
A measurement of the Higgs boson mass is presented based on the combined data samples of the ATLAS and CMS experiments at the CERN LHC in the H→γγ and H→ZZ→4ℓ decay channels. The results are obtained from a simultaneous fit to the reconstructed invariant mass peaks in the two channels and for the two experiments. The measured masses from the individual channels and the two experiments are found to be consistent among themselves. The combined measured mass of the Higgs boson is m_{H}=125.09±0.21 (stat)±0.11 (syst) GeV.
Derivation and culture of canine embryonic stem cells. - Methods in molecular biology (Clifton, N.J.)
The derivation of canine embryonic stem cells (cESCs) represents a significant achievement and opens the door to further stem cell research and therapies in the dog. Canines share a common environment with humans and exhibit a host of genetic diseases, many of which have human parallels. Thus, the canine model presents unique advantages over other currently used organisms to help develop stem cell therapies in humans. To reveal the therapeutic potential of cESCs further basic research on the molecular mechanisms controlling their pluripotency and self-renewal characteristics is needed. Herein, we present the methods for derivation and culture of cESCs. Following collection of the canine blastocyst, two derivation methods are presented; immunodissection and whole blastocyst explant. These two methods lead to cESCs differing in morphology and subculture techniques. Additional protocols for subculture of established lines, feeder-free culture, and cryopreservation protocols are also described.
Enhancement of suggestibility and imaginative ability with nitrous oxide. - Psychopharmacology
Imaginative suggestibility, a trait closely related to hypnotic suggestibility, is modifiable under some circumstances. Nitrous oxide (laughing gas) is commonly used for sedation in dentistry and is reported to be more effective when combined with appropriate suggestions.The aim of this study was to determine whether nitrous oxide inhalation alters imaginative suggestibility and imagery vividness.Thirty participants were tested twice in a within-subjects design, once during inhalation of 25% nitrous oxide and once during inhalation of air plus oxygen. Before the study, participants' expectancies regarding the effects of nitrous oxide were assessed. Participants were blinded to drug administration. During each session, participants were verbally administered detailed measures of imagination and suggestibility: the Sheehan-Betts Quality of Mental Imagery scale and the Stanford Hypnotic Susceptibility Scale Form C, minus the hypnotic induction.Imaginative suggestibility and imaginative ability (imagery vividness) were both elevated in the nitrous oxide condition. This effect was unrelated to participants' expectations regarding the effects of the drug.Nitrous oxide increased imaginative suggestibility and imaginative ability. Possible explanations of these findings are discussed with respect to the effects of N-methyl-d-aspartate antagonists and to other pharmacological effects upon suggestibility and imagination.
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. - The New England journal of medicine
The incidence and severity of herpes zoster and postherpetic neuralgia increase with age in association with a progressive decline in cell-mediated immunity to varicella-zoster virus (VZV). We tested the hypothesis that vaccination against VZV would decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia among older adults.We enrolled 38,546 adults 60 years of age or older in a randomized, double-blind, placebo-controlled trial of an investigational live attenuated Oka/Merck VZV vaccine ("zoster vaccine"). Herpes zoster was diagnosed according to clinical and laboratory criteria. The pain and discomfort associated with herpes zoster were measured repeatedly for six months. The primary end point was the burden of illness due to herpes zoster, a measure affected by the incidence, severity, and duration of the associated pain and discomfort. The secondary end point was the incidence of postherpetic neuralgia.More than 95 percent of the subjects continued in the study to its completion, with a median of 3.12 years of surveillance for herpes zoster. A total of 957 confirmed cases of herpes zoster (315 among vaccine recipients and 642 among placebo recipients) and 107 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among placebo recipients) were included in the efficacy analysis. The use of the zoster vaccine reduced the burden of illness due to herpes zoster by 61.1 percent (P<0.001), reduced the incidence of postherpetic neuralgia by 66.5 percent (P<0.001), and reduced the incidence of herpes zoster by 51.3 percent (P<0.001). Reactions at the injection site were more frequent among vaccine recipients but were generally mild.The zoster vaccine markedly reduced morbidity from herpes zoster and postherpetic neuralgia among older adults.Copyright 2005 Massachusetts Medical Society.
Re-evaluation of the glycerol-3-phosphate dehydrogenase/L-lactate dehydrogenase enzyme system. Evidence against the direct transfer of NADH between active sites. - The Biochemical journal
An investigation of the direct transfer of metabolites from rabbit muscle L-lactate dehydrogenase (LDH, EC 1.1.1.27) to glycerol-3-phosphate dehydrogenase (GPDH, EC 1.1.1.8) revealed discrepancies between theoretical predictions and experimental results. Measurements of the GPDH reaction rate at a fixed NADH concentration and in the presence of increasing LDH concentrations gave experimental results similar to those previously obtained by Srivastava, Smolen, Betts, Fukushima, Spivey & Bernhard [(1989) Proc. Natl. Acad. Sci. U.S.A. 86, 6464-6468]. However, a mathematical solution of the direct-transfer-mechanism equations as described by Srivastava et al. (1989) showed that the direct-transfer model did not adequately describe the experimental behaviour of the reaction rate at increasing LDH concentrations. In addition, experiments designed to measure the formation of an LDH4.NADH.GPDH2 complex, predicted by the direct-transfer model, indicated that no significant formation of tertiary complex occurred. An examination of other kinetic models, developed to describe the LDH/GPDH/NADH system better, revealed that the experimental results may be best explained by assuming that free NADH, and not E1.NADH, is the sole substrate for GPDH. These results suggest that direct transfer of NADH between rabbit muscle LDH and GPDH does not occur in vitro.

Map & Directions

280 Farner Place The Villages, FL 32163
View Directions In Google Maps

Nearby Doctors

280 Farner Pl
The Villages, FL 32163
352 748-8905
340 Heald Way Suite 208
The Villages, FL 32163
352 595-5762
280 Farner Pl
The Villages, FL 32163
352 741-1710
2485 Pinellas Pl
The Villages, FL 32163
352 741-1720
340 Heald Way #218
The Villages, FL 32163
352 332-2467
2485 Pinellas Pl
The Villages, FL 32163
352 741-1720
2485 Pinellas Pl
The Villages, FL 32163
352 741-1720
2485 Pinellas Pl
The Villages, FL 32163
352 741-1720
280 Farner Pl
The Villages, FL 32163
352 741-1710
340 Heald Way
The Villages, FL 32163
352 595-5762